The use of direct oral anticoagulants (DOACs) for thromboprophylaxis during neoadjuvant chemotherapy and after interval debulking surgery in ovarian cancer patients – Maximizing prevention of venous thromboembolism (VTE)
J. Michael Straughn, Teresa K.L. Boitano · 2024
Read The use of direct oral anticoagulants (DOACs) for thromboprophylaxis during neoadjuvant chemotherapy and after interval debulking surgery in ovarian cancer patients – Maximizing prevention of venous thromboembolism (VTE) by J. Michael Straughn, Teresa K.L. Boitano (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11705380.txt.
Description
Michael Straughn and Teresa Boitano survey blood clot prevention for ovarian cancer patients in this 2024 editorial. Clots strike up to a quarter of gynecologic cancer patients. They delay treatment and can kill, so prevention choices matter.
The piece introduces three studies in the same journal issue on clot prevention in these cancers. One maps silent clots after major debulking surgery and their risk factors. The editorial weighs when and which preventive anticoagulation to use, with direct oral drugs in focus. Care spans chemotherapy before surgery and recovery after it. The authors frame prevention as a way to keep cancer treatment on schedule.
Catalog record
| CREATOR | J. Michael Straughn, Teresa K.L. Boitano |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 5 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |